Navigation Links
BioMed Realty Trust Reports Third Quarter 2010 Financial Results
Date:11/3/2010

to common stockholders

$  4,832

$  4,062

$  13,331

$  41,282Adjustments:Noncontrolling interests in operating partnership

122

122

359

1,502Interest expense on exchangeable senior notes due 2030 (1)

1,681

-

4,875

-Depreciation and amortization — unconsolidated partnerships

835

662

2,192

1,986Depreciation and amortization — consolidated entities

27,774

30,953

83,159

82,767Depreciation and amortization — allocable to noncontrolling interest of consolidated joint ventures

(24)

(20)

(67)

(58)Funds from operations available to common shares and Units

$  35,220

$  35,779

$  103,849

$  127,479Funds from operations per share — diluted

$  0.28

$  0.35

$  0.86

$  1.37Weighted-average common shares and Units outstanding — diluted (2)

127,053,959

101,289,458

121,191,848

92,863,08
'/>"/>

SOURCE BioMed Realty Trust, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Reportlinker Adds Next Generation U.S. and E.U. Biomaterials/BioMedical Devices: Market Trends & Commercial Implications
2. BioMed Realty Trust Completes South San Francisco Portfolio Acquisition
3. BioMed Realty Trust to Report 2010 Third Quarter Results
4. BioSpace and BioMed Central Create Global Career Community
5. DSM Biomedical Announces Continued Partnership with Spinelab
6. BioMed Realty Trust Declares Second Quarter 2010 Common Stock and Preferred Stock Dividends
7. BioMed Realty Trust Announces Planned Filing of Resale Registration Statement in Connection With 3.75% Exchangeable Senior Notes Due 2030
8. BioMed Realty Trust Promotes Greg Lubushkin to Chief Financial Officer
9. BioMed Realty Trust Breaks Ground on 176,000 Square Foot R&D Facility for Isis Pharmaceuticals in Carlsbad, California
10. Biomedical Structures Receives Growth Capital from Ampersand Ventures to Fund Ongoing Expansion
11. BioMed Realty Trust to Webcast Company Presentation at Investor Day 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... The participants committed to not only creating unique business ... adjusting, tweaking and testing virtual models and 3D test ... , “I enjoyed being involved as a judge,” stated ... showed a commendable range exploring the technical capabilities of ... and the creativity of the contestants.” , Array Architects ...
(Date:10/1/2014)... VA (PRWEB) October 01, 2014 ... Diagnostic, Clinical Therapeutics, Healthcare IT, and Laboratory Testing industries, ... regulatory positions at the director level and above from ... struggling to stay on top of rapid breakthroughs in ... result, many diagnostic companies have been forced to fold, ...
(Date:9/30/2014)... release is available in German . ... around several quantum dots in a semiconductor layer. Quantum dots ... of atomic processes. If a short laser pulse is fired ... the quantum dot experiences a change in the electromagnetic field ... the emission of light by the dot. As soon as ...
(Date:9/30/2014)... Report Details Biosimilar drugs – ... Do you want to find sales potentials of ... for those biological drugs from 2014, helping you ... data, R&D trends, opportunities and selling prospects. In ... 2024 at overall world market, therapeutic class, molecule ...
Breaking Biology Technology:Array Architects Challenges Staff to Create with 3D Printer 2Slone Partners Meets Growing Demand as Industry Focuses on Reimbursement & Regulation 2Ultrafast remote switching of light emission 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5
... TetraLogic Pharmaceuticals , a biopharmaceutical company developing ... today announced the initiation of a Phase 1/2 clinical ... in elderly patients with acute myelogenous leukemia (AML). The ... the University of Pennsylvania and is an open-label, non-randomized ...
... Technologies, Inc. (NYSE AMEX: SNT ) announced ... for on-demand viewing. LINK:    www.retailinvestorconferences.com ... button. Senesco Technologies, presentation will be available ... from the "virtual trade booth" for the next three ...
... (OTC.BB: NWBO) (Northwest Bio) announced today that it has ... $31.5 million of liabilities through settlement, retirement and conversion. ... This restructuring reduces the Company,s liabilities from ... to $16.5 million. Only about $2.3 million of this ...
Cached Biology Technology:TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML) 2TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML) 3Senesco Technologies, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com 2Northwest Bio Implements Major Balance Sheet Clean-Up 2Northwest Bio Implements Major Balance Sheet Clean-Up 3Northwest Bio Implements Major Balance Sheet Clean-Up 4Northwest Bio Implements Major Balance Sheet Clean-Up 5
(Date:9/30/2014)... and strawberries all have in common? Unlike most ... and are diploid, these organisms are all polyploid, meaning ... and salmon have 3 and 4 sets of chromosomes, ... seem surprising, in fact most plant species are polyploid. ... century ago, but only recently, with the development of ...
(Date:9/30/2014)... Salk professor and Howard Hughes Medical Institute investigator, ... named recipients in the 2014 round of grants ... the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) ... announced September 30, provides more than $3 million ... years. , The BRAIN Initiative, launched last year, ...
(Date:9/30/2014)... of Medicine reports positive results of a phase ... subset of lung cancer marked by rearrangement of the ... with advanced non-small cell lung cancer testing positive for ... with 3 complete responses and 33 partial responses. Median ... disease to resume its growth after being slowed by ...
Breaking Biology News(10 mins):Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 3Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 4Salk scientists receive $3 million for BRAIN Initiative grant 2NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2
... On a popular children's game participants stand as close ... coaxing cells to be very, very close without actually ... challenges for cell biologists. , Now MIT researchers led ... computer science at the Harvard-MIT Division of Health Sciences ...
... Researchers at Mount Sinai School of Medicine have just ... of the microdomains of leukocytes or white blood cells. ... cells in which receptors and signaling molecules accumulate during ... to view white blood cell subsets and their forming ...
... sugars, a technique developed by University of Michigan analytical ... diagnosis and treatment options. , A growing body of ... to proteins on cancer cell surfaces as accomplices in ... keen to characterize these glycans, but traditional analytical methods ...
Cached Biology News:MIT device draws cells close -- but not too close -- together 2MIT device draws cells close -- but not too close -- together 3New imaging technique tracks traffic patterns of white blood cells 2A sweet step toward new cancer therapies 2
GeneRacer is an advanced RACE (rapid amplification of cDNA ends) technique that improves the efficiency of amplifying full-length 5' and 3' cDNA ends. With the GeneRacer Kit you can:...
Mouse Wnt-9b Affinity Purified Polyclonal Ab Keywords: Wnt 9b Protein Family: Cancer Stem Cell Markers, Wnt Ligands...
One-step, microplate or cuvet, colorimetric, linear detection range 0.6 mM to 100 mM. Procedure: 2 min....
One-step, microplate or cuvet, colorimetric, linear detection range 6 mg/dL to 100mg/dL. Procedure: 15 min....
Biology Products: